Table 4 Outcomes of patients under HR or TACE for various PVTT types
Study(year) | Treatment | Type of PVTT | Patients | Median OS(months) | 1-year(%) | 2-year(%) | 3-year(%) | 5-year(%) of Survival rates |
|---|---|---|---|---|---|---|---|---|
Fan 2001 [20] | HR | Type II | 58 | 13.0 | 59.7 | NA | 27.4 | 8.8 |
| Â | Type III | 16 | 8.0 | 29.4 | NA | 14.3 | 11.1 | |
TACE | Type II | 12 | 5.0 | 16.7 | NA | 8.3 | 0 | |
| Â | Type III | 6 | 5.5 | 33.3 | NA | 0 | 0 | |
Peng 2012 [12] | HR | Type I | 27 | NA | 81.5 | NA | 51.2 | 37.9 |
| Â | Type II | 68 | NA | 46.3 | NA | 17.2 | 17.2 | |
| Â | Type III | 83 | NA | 32.5 | NA | 3.6 | 3.6 | |
| Â | Type IV | 23 | NA | 21.7 | NA | 0 | 0 | |
TACE | Type I | 64 | NA | 41.1 | NA | 8.9 | 3.6 | |
| Â | Type II | 136 | NA | 37.9 | NA | 6.0 | 0 | |
| Â | Type III | 166 | NA | 36.1 | NA | 4.2 | 0 | |
| Â | Type IV | 46 | NA | 30.4 | NA | 4.3 | 0 | |
Liu K 2014 [17] | HR | Type I | 12 | 30.0 | 100.0 | 66.7 | 30.0 | NA |
| Â | Type II | 21 | 18.2 | 66.7 | 32.6 | 0 | NA | |
| Â | Type III | 8 | 8.9 | 25.0 | 0 | 0 | NA | |
TACE | Type I | 24 | 19.7 | 74.8 | 30.8 | 12.8 | NA | |
| Â | Type II | 32 | 10.8 | 25.9 | 9.7 | 0 | NA | |
| Â | Type III | 16 | 7.4 | 25.0 | 0 | 0 | NA | |
Lee 2016 [13] | HR | Type I | 16 | NA | 71.4 | 54.5 | 54.4 | NA |
| Â | Type II | 8 | NA | 35.0 | 0 | 0 | NA | |
TACE | Type I | 12 | NA | 50.0 | 25.0 | 16.7 | NA | |
| Â | Type II | 14 | NA | 35.7 | 7.1 | 0 | NA | |
Wang 2016 [11] | HR | Type I | 122 | 14.7 (10.7-18.7) | 57.2 | 36.1 | 21.0 | 10.0 |
| Â | Type II | 187 | 12.1 (10.0-14.2) | 50.8 | 31.0 | 22.3 | 13.3 | |
| Â | Type III | 171 | 6.2 (4.4-7.9) | 36.3 | 17.4 | 8.2 | 2.6 | |
TACE | Type I | 45 | 8.7 (4.1-13.3) | 40.0 | 17.3 | 7.3 | 0 | |
| Â | Type II | 187 | 5.3 (4.4-6.2) | 25.1 | 9.5 | 5.3 | 4.5 | |
| Â | Type III | 171 | 5.2 (3.7-6.6) | 28.1 | 12.1 | 6.7 | 5.7 |